MCID: IDP024
MIFTS: 45

Idiopathic Inflammatory Myopathy

Categories: Rare diseases, Genetic diseases

Aliases & Classifications for Idiopathic Inflammatory Myopathy

MalaCards integrated aliases for Idiopathic Inflammatory Myopathy:

Name: Idiopathic Inflammatory Myopathy 50 25
Idiopathic Inflammatory Myopathies 25 69
Idiopathic Inflammatory Myositis 50 25
Myositis 50 69
Idiopathic Inflammatory Myopathy, Familial 50
Myopathies Idiopathic Inflammatory 52
Inflammatory Myopathy, Idiopathic 25
Iim 50
Imm 50

Classifications:



Summaries for Idiopathic Inflammatory Myopathy

NIH Rare Diseases : 50 idiopathic inflammatory myopathy refers to a group of conditions that affect the skeletal muscles (muscles used for movement). although the condition can be diagnosed at any age, idiopathic inflammatory myopathy most commonly occurs in adults between ages 40 and 60 years or in children between ages 5 and 15 years. signs and symptoms of the condition include muscle weakness, joint pain and fatigue. there are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis, which are each associated with unique features. as the name suggests, the cause of the condition is currently unknown (idiopathic). however, researchers suspect that it may occur due to a combination of genetic and environmental factors. treatment is supportive and based on the signs and symptoms present in each person. last updated: 2/17/2016

MalaCards based summary : Idiopathic Inflammatory Myopathy, also known as idiopathic inflammatory myopathies, is related to rheumatoid arthritis and congenital disorder of glycosylation, type iim, and has symptoms including back pain, muscle cramp and muscle rigidity. An important gene associated with Idiopathic Inflammatory Myopathy is TRIM21 (Tripartite Motif Containing 21), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Simvastatin and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, lung and tongue, and related phenotype is Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers.

Genetics Home Reference : 25 Idiopathic inflammatory myopathy is a group of disorders characterized by inflammation of the muscles used for movement (skeletal muscles). Idiopathic inflammatory myopathy usually appears in adults between ages 40 and 60 or in children between ages 5 and 15, though it can occur at any age.

Wikipedia : 72 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

Related Diseases for Idiopathic Inflammatory Myopathy

Diseases related to Idiopathic Inflammatory Myopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis 28.0 HLA-B HLA-DQB1 HLA-DRB1 IL1A
2 congenital disorder of glycosylation, type iim 12.0
3 necrotizing autoimmune myopathy 11.2
4 slc35a2-cdg 11.1
5 type 2m von willebrand disease 10.8
6 myopathy 10.7
7 ramsay hunt syndrome i 10.3 HLA-B HLA-DRB1
8 migraine with brainstem aura 10.3 HLA-B HLA-DRB1
9 hernia of ovary and fallopian tube 10.3 HLA-B HLA-DRB1
10 epstein-barr virus hepatitis 10.3 HLA-DRB1 IL1A
11 not otherwise specified 3-mga-uria type 10.3 HLA-B HLA-DRB1
12 aseptic meningitis 10.3 HLA-B HLA-DRB1
13 acanthoma 10.3 HLA-B HLA-DRB1
14 myositis 10.2
15 optic atrophy 7 10.2 HLA-B IL1A
16 disease of mental health 10.2 HLA-B HLA-DRB1
17 iida kannari syndrome 10.2 HLA-DRB1 IL1A
18 eye carcinoma in situ 10.2 HLA-B HLA-DRB1
19 acute cholangitis 10.2 HLA-B HLA-DRB1
20 emphysema, congenital lobar 10.2 HLA-B HLA-DRB1
21 mesenchymal cell neoplasm 10.2 HLA-DRB1 IL1A
22 isthmus cancer 10.2 HLA-B HLA-DRB1
23 dermatomyositis 10.1
24 interstitial lung disease 10.1
25 lung disease 10.1
26 fruit allergy 10.0 HLA-DQB1 HLA-DRB1
27 breast hemangiopericytoma 10.0 HLA-DQB1 HLA-DRB1
28 biemond syndrome 10.0 HLA-DQB1 HLA-DRB1
29 light chain deposition disease 10.0 HLA-DQB1 HLA-DRB1
30 juvenile sialidosis type 2 10.0 HLA-DQB1 HLA-DRB1
31 reese retinal dysplasia 10.0 HLA-DQB1 HLA-DRB1
32 mosaic trisomy 1 10.0 HLA-DQB1 HLA-DRB1
33 autoimmune retinopathy 10.0 HLA-DQB1 HLA-DRB1
34 limb-body wall complex 10.0 HLA-DQB1 HLA-DRB1
35 transient retinal arterial occlusion 10.0 HLA-DQB1 HLA-DRB1
36 kaposi sarcoma 10.0 HLA-DRB1 IL1A
37 ovarian surface papilloma 10.0 HLA-DQB1 HLA-DRB1
38 pellagra like syndrome 10.0 HLA-DQB1 HLA-DRB1
39 clear cell adenocarcinoma of ovary 10.0 HLA-DQB1 HLA-DRB1
40 lymphocytic colitis 10.0 HLA-DQB1 HLA-DRB1
41 polymyositis 10.0
42 papillary squamous carcinoma 10.0 HLA-DQB1 HLA-DRB1
43 reproductive system disease 9.9 HLA-DQB1 HLA-DRB1
44 oculogyric crisis 9.9 HLA-DQB1 HLA-DRB1
45 infantile hypotonia 9.9 HLA-DQB1 HLA-DRB1
46 moderately severe hemophilia b 9.9 HLA-DQB1 HLA-DRB1
47 epidermolysis bullosa simplex superficialis 9.9 HLA-DQB1 HLA-DRB1
48 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 9.9 HLA-B HLA-DQB1
49 endotheliitis 9.9
50 esophageal candidiasis 9.9 HLA-B IL1A

Graphical network of the top 20 diseases related to Idiopathic Inflammatory Myopathy:



Diseases related to Idiopathic Inflammatory Myopathy

Symptoms & Phenotypes for Idiopathic Inflammatory Myopathy

UMLS symptoms related to Idiopathic Inflammatory Myopathy:


back pain, muscle cramp, muscle rigidity, muscle spasticity, myoclonus, sciatica, torticollis, muscle weakness, myalgia

GenomeRNAi Phenotypes related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers GR00195-A-3 8.62 IL1A TRIM21

Drugs & Therapeutics for Idiopathic Inflammatory Myopathy

Drugs for Idiopathic Inflammatory Myopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
2
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
5
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
6 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
7
Pirfenidone Investigational Phase 4 53179-13-8 40632
8 Anticholesteremic Agents Phase 4,Phase 2
9 Antimetabolites Phase 4,Phase 3,Phase 2
10 Calcium, Dietary Phase 4,Phase 2,Early Phase 1
11 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3
12 Hypolipidemic Agents Phase 4,Phase 2
13 Lipid Regulating Agents Phase 4,Phase 2
14 Rosuvastatin Calcium Phase 4 147098-20-2
15 Anti-HIV Agents Phase 4
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Retroviral Agents Phase 4
18 Antiviral Agents Phase 4,Phase 1
19 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
20 Reverse Transcriptase Inhibitors Phase 4
21
Tenofovir Phase 4 147127-20-6 464205
22 Vaccines Phase 4
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Adrenocorticotropic Hormone Phase 4,Phase 2
31 beta-endorphin Phase 4,Phase 2
32 Melanocyte-Stimulating Hormones Phase 4,Phase 2
33 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Atorvastatin Calcium Phase 4 134523-03-8
37
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
38
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
39
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
40
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
41
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
42
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
43
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
44
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
45
Infliximab Approved Phase 2, Phase 3 170277-31-3
46
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
47
Lenograstim Approved Phase 3,Phase 1 135968-09-1
48
Mesna Approved Phase 2, Phase 3 3375-50-6 598
49
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
50
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 185243-69-0

Interventional clinical trials:

(show top 50) (show all 139)

id Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
5 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
6 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
7 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
8 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
9 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
10 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Unknown status NCT00504348 Phase 2, Phase 3 Tacrolimus
11 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
12 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
13 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
14 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Completed NCT02573467 Phase 3 Bimagrumab;Placebo
15 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
16 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
17 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
18 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
19 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
20 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
21 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
22 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
23 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
24 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
25 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
26 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
27 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
28 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
29 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Active, not recruiting NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
30 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP Not yet recruiting NCT03312634 Phase 3 Palovarotene
31 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
32 Statins for the Early Treatment of Sepsis Unknown status NCT00528580 Phase 2 Simvastatin;Identical-appearing placebo
33 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
34 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
35 Alemtuzumab to Treat Sporadic Inclusion Body Myositis Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
36 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
37 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
38 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
39 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
40 An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Completed NCT02190747 Phase 2 Palovarotene;Placebo
41 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
42 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
43 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
44 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
45 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
46 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
47 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2 BAF312 0.5 mg;BAF312 2 mg;BAF312 10 mg;Placebo to BAF312
48 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
49 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
50 Study of Arimoclomol in Inclusion Body Myositis (IBM) Recruiting NCT02753530 Phase 2 Arimoclomol

Search NIH Clinical Center for Idiopathic Inflammatory Myopathy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Idiopathic Inflammatory Myopathy

Anatomical Context for Idiopathic Inflammatory Myopathy

MalaCards organs/tissues related to Idiopathic Inflammatory Myopathy:

39
Skeletal Muscle, Lung, Tongue, Bone, Eye, Skin, Kidney

Publications for Idiopathic Inflammatory Myopathy

Articles related to Idiopathic Inflammatory Myopathy:

(show top 50) (show all 137)
id Title Authors Year
1
Investigating Idiopathic Inflammatory Myopathy; Initial Cross Speciality Experience with Use of the Extended Myositis Antibody Panel. ( 28567235 )
2017
2
Multiple values of (18)F-FDG PET/CT in idiopathic inflammatory myopathy. ( 28831580 )
2017
3
AIIMDs: An Integrated Framework of Automatic Idiopathic Inflammatory Myopathy Diagnosis for Muscle. ( 28422672 )
2017
4
Ro52/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies. ( 27936488 )
2017
5
Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis. ( 28493173 )
2017
6
Necrotizing Autoimmune Myopathy: A Rare Variant of Idiopathic Inflammatory Myopathies. ( 28660228 )
2017
7
Is it cardiac involvement mimicking acute myocardial infarction in idiopathic inflammatory myopathy? ( 28672937 )
2017
8
Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. ( 28814428 )
2017
9
The PTPN22 gene is associated with idiopathic inflammatory myopathy. ( 27312665 )
2017
10
Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies. ( 27642533 )
2016
11
High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. ( 27412148 )
2016
12
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. ( 27878344 )
2016
13
Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. ( 27279002 )
2016
14
Case Report: Elevated CPK, an indicator of idiopathic inflammatory myopathy? ( 27540467 )
2016
15
Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: A single center study. ( 26998007 )
2016
16
Autoantibodies in adult patients with idiopathic inflammatory myopathies in Buenos Aires. ( 27295700 )
2016
17
Long-term follow-up of patients with idiopathic inflammatory myopathy at Waitemata District Health Board. ( 26914299 )
2016
18
Necrotizing Autoimmune Myopathy: A Unique Subset of Idiopathic Inflammatory Myopathy. ( 27660937 )
2016
19
The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies. ( 27522114 )
2016
20
Seasonality of birth patterns in an Australian cohort of patients with biopsy-confirmed idiopathic inflammatory myopathy. ( 27170240 )
2016
21
PET/CT scan revealing active idiopathic inflammatory myopathy with normal serum sarcoplasmic enzymes levels. ( 26968020 )
2016
22
213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. ( 27312023 )
2016
23
Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. ( 27504827 )
2016
24
Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. ( 27894310 )
2016
25
Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. ( 27388770 )
2016
26
Idiopathic Inflammatory Myopathies: Clinical Approach and Management. ( 27242652 )
2016
27
Diagnosis and classification of idiopathic inflammatory myopathies. ( 27320359 )
2016
28
Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. ( 27173897 )
2016
29
High resolution manometry in patients with idiopathic inflammatory myopathy: Elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. ( 27935079 )
2016
30
Increased osteopontin in muscle and serum from patients with idiopathic inflammatory myopathies. ( 25936410 )
2015
31
Juvenile Idiopathic Inflammatory Myopathy in a Patient With Dyskeratosis Congenita Due to C16orf57 Mutation. ( 26535771 )
2015
32
Discovery of new biomarkers of idiopathic inflammatory myopathy. ( 25681646 )
2015
33
Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy. ( 26259546 )
2015
34
Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy. ( 26922197 )
2015
35
Extrapulmonary Tuberculosis Infection in Mexican Patients With Idiopathic Inflammatory Myopathies. ( 26308355 )
2015
36
Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. ( 25673126 )
2015
37
Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy. ( 25490616 )
2015
38
HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases. ( 25761565 )
2015
39
Survival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort. ( 26190563 )
2015
40
Vitamin D receptor gene polymorphisms and haplotypes in Hungarian patients with idiopathic inflammatory myopathy. ( 25649962 )
2015
41
Infantile-onset LMNA-associated Muscular Dystrophy Mimicking Juvenile Idiopathic Inflammatory Myopathy. ( 26034236 )
2015
42
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. ( 26424665 )
2015
43
Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy. ( 26337070 )
2015
44
Idiopathic Inflammatory Myopathy Treated With High-Dose Immunoablative Cyclophosphamide--A Long-term Follow-up Study. ( 26457632 )
2015
45
Strategies for evaluating idiopathic inflammatory myopathy disease susceptibility genes. ( 25182674 )
2014
46
Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. ( 24812289 )
2014
47
Patient-reported Outcomes and Adult Patients' Disease Experience in the Idiopathic Inflammatory Myopathies. Report from the OMERACT 11 Myositis Special Interest Group. ( 24429182 )
2014
48
Human I^-defensin-3 correlates with muscle fibre degeneration in idiopathic inflammatory myopathies. ( 23608825 )
2014
49
Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome: recent advances. ( 25203119 )
2014
50
The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. ( 25359220 )
2014

Variations for Idiopathic Inflammatory Myopathy

Expression for Idiopathic Inflammatory Myopathy

Search GEO for disease gene expression data for Idiopathic Inflammatory Myopathy.

Pathways for Idiopathic Inflammatory Myopathy

Pathways related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 HLA-B HLA-DQB1 HLA-DRB1 IL1A TRIM21
2
Show member pathways
13.05 HLA-B HLA-DQB1 HLA-DRB1 TRIM21
3
Show member pathways
12.61 HLA-B HLA-DQB1 HLA-DRB1
4
Show member pathways
12.46 HLA-B HLA-DQB1 HLA-DRB1 IL1A TRIM21
5
Show member pathways
12.41 HLA-B HLA-DQB1 HLA-DRB1 IL1A
6
Show member pathways
12.31 HLA-B HLA-DQB1 HLA-DRB1 IL1A
7
Show member pathways
12.26 HLA-DQB1 HLA-DRB1 IL1A
8 12.09 HLA-B HLA-DQB1 HLA-DRB1
9 11.98 HLA-B HLA-DQB1 HLA-DRB1
10
Show member pathways
11.93 HLA-DQB1 HLA-DRB1 IL1A
11 11.89 HLA-DQB1 HLA-DRB1 IL1A
12
Show member pathways
11.82 HLA-B IL1A
13 11.79 HLA-B HLA-DQB1 HLA-DRB1
14 11.74 HLA-B HLA-DQB1 HLA-DRB1
15
Show member pathways
11.64 HLA-DQB1 HLA-DRB1
16 11.6 HLA-DQB1 HLA-DRB1
17
Show member pathways
11.5 HLA-DQB1 HLA-DRB1
18 11.43 HLA-DQB1 HLA-DRB1
19 11.42 HLA-DQB1 HLA-DRB1 IL1A
20
Show member pathways
11.42 HLA-B HLA-DQB1 HLA-DRB1 TRIM21
21 11.31 HLA-DQB1 HLA-DRB1
22 11.29 HLA-DQB1 HLA-DRB1 IL1A
23 11 HLA-DRB1 IL1A

GO Terms for Idiopathic Inflammatory Myopathy

Cellular components related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.61 HLA-B HLA-DQB1 HLA-DRB1
2 trans-Golgi network membrane GO:0032588 9.4 HLA-DQB1 HLA-DRB1
3 endocytic vesicle membrane GO:0030666 9.37 HLA-DQB1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.32 HLA-DQB1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.26 HLA-DQB1 HLA-DRB1
6 MHC class II protein complex GO:0042613 9.16 HLA-DQB1 HLA-DRB1
7 ER to Golgi transport vesicle membrane GO:0012507 9.13 HLA-B HLA-DQB1 HLA-DRB1
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-B HLA-DQB1 HLA-DRB1

Biological processes related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.62 HLA-B HLA-DQB1 HLA-DRB1 IL1A
2 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.43 HLA-DQB1 HLA-DRB1
3 T cell costimulation GO:0031295 9.4 HLA-DQB1 HLA-DRB1
4 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.37 HLA-DQB1 HLA-DRB1
5 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.26 HLA-DQB1 HLA-DRB1
6 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DQB1 HLA-DRB1
7 antigen processing and presentation GO:0019882 9.13 HLA-B HLA-DQB1 HLA-DRB1
8 interferon-gamma-mediated signaling pathway GO:0060333 8.92 HLA-B HLA-DQB1 HLA-DRB1 TRIM21

Molecular functions related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1
2 peptide antigen binding GO:0042605 8.8 HLA-B HLA-DQB1 HLA-DRB1

Sources for Idiopathic Inflammatory Myopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....